Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for CancerCARE for Life ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The University of Minnesota and Essentia said in January they were in early discussions to form a nonprofit entity.

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

Under the terms of the agreement, which was unanimously approved by the boards ... of Nevro's technology and bring much ...

Q2 2025 Earnings Call February 4, 2025 8:00 AM ETCompany ParticipantsBen Krasinski - Senior Director, IRMichael J.

The Department of Justice (DOJ) released its annual False Claims Act (FCA) enforcement statistics on January 15, 2025, ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem cell transplant ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder hope of a cure. Campaigners reacted with joy as health officials approved a ...